Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Diabetes Obes MetabJul 6, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Mengyun Lei, Qiongyan Lin, Yongwen Zhou et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the efficacy and safety of tubeless hybrid closed-loop (HCL) systems in managing type 1 diabetes (T1D) by analyzing four randomized controlled trials with 514 participants. The study found that tubeless HCL significantly improved time in range (TIR) by 15.31% and reduced glycated hemoglobin (HbA1c) by 0.46% compared to standard care, without increasing insulin doses or safety risks.

Key findings

  • Tubeless HCL improved time in range (TIR) by 15.31% compared to standard care.
  • Glycated hemoglobin (HbA1c) decreased by 0.46% with tubeless HCL.
  • Lower levels of time above range (TAR) and coefficient of variability (CV) were observed in the tubeless HCL group.
  • No significant differences in severe hypoglycaemia (SH) or diabetic ketoacidosis (DKA) were noted.

Why it matters

Improving glycaemic control in type 1 diabetes is crucial for reducing long-term complications. This study suggests that tubeless HCL systems may offer a beneficial alternative to standard care without increasing safety risks.

Source

PubMed · PMID 42410321Free full text on PubMed Central

Published in Diabetes Obes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.